Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

PURPOSE: Sonic hedgehog (SHH), an activating ligand of smoothened (SMO), is overexpressed in > 70% of pancreatic cancers (PCs). We investigated the impact of vismodegib, an SHH antagonist, plus gemcitabine (GV) or gemcitabine plus placebo (GP) in a multicenter phase Ib/randomized phase II trial a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Catenacci, Daniel V.T., Junttila, Melissa R., Karrison, Theodore, Bahary, Nathan, Horiba, Margit N., Nattam, Sreenivasa R., Marsh, Robert, Wallace, James, Kozloff, Mark, Rajdev, Lakshmi, Cohen, Deirdre, Wade, James, Sleckman, Bethany, Lenz, Heinz-Josef, Stiff, Patrick, Kumar, Pankaj, Xu, Peng, Henderson, Les, Takebe, Naoko, Salgia, Ravi, Wang, Xi, Stadler, Walter M., de Sauvage, Frederic J., Kindler, Hedy L.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2015
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4678179/
https://ncbi.nlm.nih.gov/pubmed/26527777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.62.8719
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars